Stay ahead of every GLP-1 development
Free email newsletter. We send roughly 1–2 emails per month - only when something actually changes that affects your treatment, pricing, or eligibility.
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.
No spam. Unsubscribe anytime. We never sell your email. By submitting, you agree to our Privacy Policy.
What we send
🆕
New FDA approvals
CagriSema, retatrutide, and future molecules - the day they're approved with launch pricing. (Foundayo / orforglipron approved April 1, 2026; we cover ongoing pricing and coverage changes.)
💸
Price drops
LillyDirect, NovoCare, telehealth platforms - when they cut prices, you'll know within hours.
📊
Clinical trial results
New efficacy data from STEP, SURMOUNT, SURPASS, REDEFINE, ATTAIN, TRIUMPH trials - what it means for you.
⚠️
FDA recalls & safety
Black-box warnings, label updates, batch recalls - information for your prescriber conversation.
🏥
Insurance policy changes
Major insurer formulary changes, employer plan exclusions, new state Medicaid coverage.
🧠
Independent analysis
Honest takes on what changes matter and what's just marketing. Not sponsored by drug manufacturers.
What we don't do
- No spam. 1–2 emails per month, max. If nothing changes, we don't email.
- No selling your email. Ever. Period.
- No clickbait. If a headline says "FDA approved X," that actually happened.
- No advertorials disguised as content. Sponsored placements (if any) are clearly labeled.
Recent example topics
Oct 2026Correction: our 50-state Medicaid tracker previously showed only 3 or 4 states covering weight-loss GLP-1s because many rows had not been checked against state sources. Re-checking every state against its own documents, 10 cover as of October 12 and 7 programs ended coverage in 2026 (Rhode Island on October 1); each state page now shows its sources and check date
Aug 202650-state Medicaid tracker updated: more states were dropping weight-loss GLP-1 coverage than adding it
Jul 2026Medicare GLP-1 Bridge went live July 1: $50/month Part D copay for Foundayo, Wegovy, and Zepbound KwikPen, with BMI-based eligibility
Jul 2026MassHealth's weight-loss GLP-1 exclusion took effect July 3 (announced as July 1); coverage continues for other approved indications, and requests for members under 21 are reviewed under EPSDT
Jul 2026Delaware state employee plan raised the weight-loss GLP-1 copay to $200 per 30-day supply, while diabetes use stays at $32
May 2026Foundayo Savings Card terms published: $25 covered, $149/$199/$299 non-covered by dose, $50/mo Medicare path from July 1 (launched as the GLP-1 Bridge, not the postponed BALANCE Model as initially reported)
Apr 2026FDA approves Foundayo (orforglipron): first daily oral GLP-1 with no food restrictions, $149/mo via LillyDirect
Apr 2026Wegovy oral 25 mg launched - full pricing breakdown vs injection
Mar 2026ASA updates perioperative hold guidance: liquid diet over 24h
Feb 2026LillyDirect adds Mounjaro self-pay vials at $349/mo
Jan 2026FDA approves first oral semaglutide for chronic weight management
Dec 2025CagriSema NDA accepted - what 20.4% weight loss means in practice
Why subscribe?
The GLP-1 landscape is changing faster than any niche of healthcare in a generation. Drug launches, price cuts, FDA decisions, and insurance changes happen monthly. Reading BabyCenter or WebMD weeks later is too slow. We do the watching for you and only email when something genuinely affects your access, cost, or safety.
Medical disclaimer: This calculator provides estimates only based on phase 3 clinical trial data and publicly listed prices. It is not medical advice. Real-world weight loss varies significantly. Consult a licensed healthcare provider before starting any medication.